Sensei Biotherapeutics, Inc. (SNSE)

In the past six months, Sensei Biotherapeutics reported Q3 2025 earnings, initiated a strategic review, and presented clinical data at the ESMO Congress 2025. There was a change in leadership structure in November 2025, and the development of solnerstotug was halted. The company executed a 1-for-20 reverse stock split in June 2025. As of early February 2026, the stock price had increased by 13.87% in the past month, although it had decreased by 1.14% over the last 12 months, and company insiders sold $287,280.00 worth of stock.

As a clinical-stage biopharmaceutical company without commercialized products, Sensei Biotherapeutics does not have direct demand seasonality information. The company's revenue is primarily non-operating, derived from interest earned on cash and marketable securities.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and infectious diseases, utilizing its TMAb™ platform. The company's lead product candidate, solnerstotug, was halted in late 2025, and its pipeline includes other investigational monoclonal antibodies in early development stages for solid tumors, such as SNS-102 (VSIG4), SNS-103 (ENTPDase/CD39), and SNS-201 (VISTAxCD28).

Sensei Biotherapeutics, Inc. is headquartered in Rockville, Maryland, United States, and maintains a presence in Boston, Massachusetts.

Sensei Biotherapeutics has received a "Moderate Buy" consensus rating from analysts, but some analysts have assigned a general "sell" rating to the stock. News coverage has been relatively low, and investor sentiment has decreased. Key events impacting the company's reputation include the initiation of a strategic review, a change in leadership, and the halting of solnerstotug.

The ownership structure of Sensei Biotherapeutics, Inc. includes institutional investors, insiders, and the general public. Major institutional shareholders include VTSMX, Ikarian Capital, LLC, and Catalio Capital Management, LP. Insiders collectively hold 23.20% of the stock, while institutional ownership stands at 10.50%.